Compare ICFI & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | VCEL |
|---|---|---|
| Founded | 1969 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2006 | 1996 |
| Metric | ICFI | VCEL |
|---|---|---|
| Price | $79.67 | $37.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $99.25 | $57.50 |
| AVG Volume (30 Days) | 121.6K | ★ 398.4K |
| Earning Date | 04-03-2026 | 05-18-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | 33.79 | ★ 60.00 |
| EPS | ★ 4.01 | 0.32 |
| Revenue | ★ $1,229,162,000.00 | $276,259,000.00 |
| Revenue This Year | N/A | $18.02 |
| Revenue Next Year | $2.52 | $18.52 |
| P/E Ratio | $18.74 | ★ N/A |
| Revenue Growth | 3.72 | ★ 16.45 |
| 52 Week Low | $72.03 | $29.24 |
| 52 Week High | $101.71 | $52.06 |
| Indicator | ICFI | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 53.41 |
| Support Level | $74.24 | $34.61 |
| Resistance Level | $88.80 | $38.41 |
| Average True Range (ATR) | 3.53 | 1.70 |
| MACD | -0.43 | 0.24 |
| Stochastic Oscillator | 40.15 | 80.93 |
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.